This inventor holds 3 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Leland Stanford Junior University. Active years: 2016-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Stanford, CA (US) (2016)
- Redwood City, CA (US) (2022)
Company Filing History:
Years Active: 2016-2026
Title: Edda Spiekerkoetter: Innovator in Pulmonary Hypertension Treatments
Introduction
Edda Spiekerkoetter is a prominent inventor based in Redwood City, CA (US). She has made significant contributions to the field of pulmonary hypertension through her innovative research and patented inventions. With a total of 3 patents, her work focuses on developing effective treatments for this serious condition.
Latest Patents
Edda's latest patents include groundbreaking methods for treating pulmonary hypertension and emphysema. One of her notable inventions is related to Enzastaurin and fragile histidine triad (FHIT)-increasing agents. This invention provides methods for the treatment or prevention of pulmonary hypertension and emphysema using agents that increase the activity of FHIT, such as Enzastaurin. The invention is based on evidence that Enzastaurin prevents and reverses pulmonary hypertension induced in animal model systems by up-regulating FHIT and/or BMPR2. Another significant patent involves the use of FK506 for the treatment of pulmonary arterial hypertension. This method reduces pulmonary arterial hypertension in mammals by administering FK506 to those with defective MBPR2 signaling, effectively lowering blood pressure in the pulmonary artery.
Career Highlights
Edda Spiekerkoetter is affiliated with Leland Stanford Junior University, where she conducts her research and develops her innovative treatments. Her work has garnered attention in the medical community for its potential to improve the lives of patients suffering from pulmonary hypertension.
Collaborations
Edda collaborates with talented individuals in her field, including Svenja Dannewitz Prosseda and Xuefei Tian. These collaborations enhance her research efforts and contribute to the advancement of treatments for pulmonary hypertension.
Conclusion
Edda Spiekerkoetter's contributions to the field of pulmonary hypertension are invaluable. Her innovative patents and research efforts continue to pave the way for new treatment options, demonstrating her commitment to improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile